Skip to content
Business Company News, Medical Health Aged Care

CIMIC’s Leighton Asia wins major hospital expansion project in Hong Kong

CIMIC Group 2 mins read

CIMIC Group company Leighton Asia, in joint venture, has been selected by the Hong Kong Hospital Authority to undertake the A$4.3 billion North District Hospital (NDH) expansion project.

The project, which will generate revenue of up to A$2.4 billion for Leighton Asia, will elevate the health infrastructure in the North District of Hong Kong and provide around 1,500 additional hospital beds.

CIMIC Group Executive Chairman Juan Santamaria said: “Modern healthcare infrastructure is foundational to the well-being of communities. We are proud to bring our experience in delivering health facilities and our ‘hospital-first’ approach to this project, which puts the needs of health workers, patients, and community at the forefront. We look forward to working with the Hong Kong Hospital Authority to deliver this upgrade for Hong Kong’s Northern District.”

Leighton Asia Managing Director Brad Davey said: “Leighton Asia, is proud to be part of the team chosen for the North District Hospital expansion, a project that will set new standards in patient care and medical excellence. Our extensive experience in healthcare construction, combined with our deep understanding of local and international standards, uniquely equips us to deliver this state-of-the-art facility.”

The joint venture between Leighton Asia and China Railway First Group will construct the main works for a new acute block, a 20-storey structure covering a construction floor area of 380,000sq m, a single basement level and a mezzanine floor, and various external and landscaping works.


About us:

CIMIC Group is an engineering-led construction, mining, services and public private partnerships leader working across the lifecycle of assets, infrastructure and resources projects. CIMIC Group comprises our construction businesses CPB Contractors, Leighton Asia and Broad, our mining and mineral processing companies Thiess (joint control) and Sedgman, our services specialist UGL and our development and investment arm Pacific Partnerships – all supported by our in-house engineering consultancy EIC Activities. Our mission is to generate sustainable returns by delivering innovative and competitive solutions for clients and safe, fulfilling careers for our people. With a history since 1899, and around 30,000 people in around 20 countries, we strive to be known for our principles of Integrity, Accountability, Innovation and Delivery, underpinned by Safety.


Contact details:

Ms Fiona Tyndall, Communications T+61 2 9925 6188

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.